Table 5.
Final multiple regression model for outcome of COVID-19 hospitalization.
| Variables | p | Odds ratio | 95% confidence interval |
|---|---|---|---|
| Age in years | 0.032 | 1.008 | 1.001–1.015 |
| Female sex | < 0.001 | 0.651 | 0.570–0.744 |
| Diabetes duration ≤ 2 years | 0.057 | 0.707 | 0.495–1.010 |
| Diabetes duration in years | 0.599 | 1.005 | 0.987–1.022 |
| Insulin | 0.015 | 1.261 | 1.046–1.520 |
| SARS-cov-2 vaccination dose 1 | 0.264 | 1.151 | 0.899–1.474 |
| SARS-cov-2 vaccination dose 2 | < 0.001 | 0.398 | 0.307–0.517 |
| SARS-cov-2 vaccination booster | < 0.001 | 0.336 | 0.264–0.428 |
| Malignant neoplasms | 0.156 | 1.140 | 0.951–1.366 |
| Hypertensive diseases | < 0.001 | 1.451 | 1.170–1.799 |
| Ischaemic heart diseases | 0.054 | 1.138 | 0.998–1.297 |
| Cerebrovascular diseases | 0.275 | 1.099 | 0.927–1.303 |
| Chronic lower respiratory diseases | < 0.001 | 1.482 | 1.189–1.847 |
| Other chronic obstructive pulmonary disease | 0.833 | 1.027 | 0.802–1.314 |
| Chronic kidney disease | < 0.001 | 1.360 | 1.140–1.623 |
| SGLT-2 inhibitors | < 0.001 | 0.555 | 0.418–0.737 |
| Sulfonylureas | 0.018 | 1.184 | 1.029–1.362 |
| GLP-1 analogues | 0.142 | 0.784 | 0.567–1.084 |
| Metformin | 0.743 | 1.024 | 0.887–1.183 |
P of the multivariate model < 0.001.
Bolded text in table represents variables with statistically significant association to outcome; Univariate models are available in Additional file 2.